300-22 | A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of Selinexor in maintenance therapy after systemic therapy for patients with P53 Wild-Type, advanced or recurrent endometrial carcinoma

Overview

“A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma”

The purpose of this study is to evaluate the efficacy and safety of Selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma, who have achieved a partial response or complete response after completing at least 12 weeks of platinum-based therapy.